Desh Rakshak AushdhalayaBOM:531521 61 Net Margin % is 8.54% as of Mar. 2026, which is 32% above its 10-year median of 6.47. GuruFocus rates BOM:531521 with a GF Score™ of 61/100 and a GF Value™ of ₹18.38 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 957 Drug Manufacturers companies, Desh Rakshak Aushdhalaya ranks better than 57.89% on this metric.
The historical rank and industry rank for Desh Rakshak Aushdhalaya's Net Margin % or its related term are showing as below:
BOM:531521'
s Net Margin % Range Over the Past 10 Years
Min: 5.54 Med: 6.47 Max: 7.99
Current: 7.99
BOM:531521's Net Margin % is ranked better than 57.89% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs BOM:531521: 7.99
Desh Rakshak Aushdhalaya (BOM:531521) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Desh Rakshak Aushdhalaya Net Margin % Related Terms
Desh Rakshak Aushdhalaya Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Desh Rakshak Aushdhalaya's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Desh Rakshak Aushdhalaya Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Desh Rakshak Aushdhalaya's Net Margin % distribution charts can be found below:
* The bar in red indicates where Desh Rakshak Aushdhalaya's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Desh Rakshak Aushdhalaya (BOM:531521) has a Net Margin % of 8.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Desh Rakshak Aushdhalaya and its competitors. This is 32% above median its historical median of 6.47. Over the past decade, Desh Rakshak Aushdhalaya's Net Margin % has ranged from 5.54 to 7.99. According to the industry distribution chart, Desh Rakshak Aushdhalaya ranks #403 out of 957 companies in the Drug Manufacturers industry, placing it in the top 42.1%.
Is Desh Rakshak Aushdhalaya's Net Margin % too high?
Desh Rakshak Aushdhalaya's current Net Margin % of 8.54% is 32% above median its 10-year median of 6.47. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 7.99. The Drug Manufacturers industry median Net Margin % is 5.58. Desh Rakshak Aushdhalaya's value of 8.54% is 53% above this industry median. Based on the distribution chart, Desh Rakshak Aushdhalaya ranks #403 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Desh Rakshak Aushdhalaya has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Desh Rakshak Aushdhalaya's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Desh Rakshak Aushdhalaya ranks #403 out of 957 companies for Net Margin %. This puts Desh Rakshak Aushdhalaya in the upper half of its industry. The industry median Net Margin % is 5.58. Desh Rakshak Aushdhalaya's value of 8.54% is 53% above this benchmark. Historically, Desh Rakshak Aushdhalaya's own Net Margin % has ranged from 5.54 to 7.99 over the past decade. While the company's 10-year median is 6.47 vs. the industry median of 5.58, Desh Rakshak Aushdhalaya has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Desh Rakshak Aushdhalaya's current Net Margin % of 8.54% is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Desh Rakshak Aushdhalaya and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Desh Rakshak Aushdhalaya's current Net Margin % is 8.54%, which is 32% above median its own 10-year median of 6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Desh Rakshak Aushdhalaya stock overvalued right now?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya (BOM:531521) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.38, compared to a current price of ₹32.59 — trading 77.3% above its estimated fair value. The current Net Margin % is 8.54%, which is 32% above median its 10-year median of 6.47 and 53% above the Drug Manufacturers industry median of 5.58. Desh Rakshak Aushdhalaya's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Desh Rakshak Aushdhalaya (BOM:531521), the current Net Margin % is 8.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Desh Rakshak Aushdhalaya (BOM:531521) Overvalued in 2026?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya stock appears to be overvalued.
The current stock price of ₹32.59 is trading 77.3% above its estimated GF Value™ of ₹18.38.
GuruFocus considers Desh Rakshak Aushdhalaya to be Significantly Overvalued.
Key valuation signals for BOM:531521:
Net Margin %: 8.54% (32% above median its 10-year median of 6.47)
GF Value™: ₹18.38 vs. price of ₹32.59 (77.3% above fair value)
Industry Position: 53% above the Drug Manufacturers median (#403 of 957)
No single metric tells the full story. See the BOM:531521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Desh Rakshak Aushdhalaya Ltd manufactures and sells ayurvedic and herbal products in India. The firm offers ayurvedic patents & proprietary medicines with herbs. It provides classical and patent medicines in tablet and capsule, powder, and liquid forms. Products ranging from AmalkiChurna, Ashwagandha Tablet, TriphalaChurna, LavanaBhaskarChurna, Sat-Shilajeet, ShunthiChurna, HingwadiChurna, GasharVati, BuddhivardhakYog, Balamrit, LodhraChurna, and Others.
61GF Score
Get the complete analysis for BOM:531521
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531521 has been successfully added to your 
